|Date: Tuesday, September 15, 2020|
Time: 9:00am PDT / 12:00pm EDT
Duration: 1 hour
The measurement of multiple biological activities following drug treatment of cell-based systems, a central tenant of phenotypic screening and profiling, is experiencing a renaissance in drug discovery as companies look beyond biochemical approaches to complex cell and tissue systems with high physiological relevance. Previously, challenges of data interpretation and limited data analytics, unclear relevance or benefit to human disease, and lack of throughput and leadership support for this approach hindered broad adoption. Many of these issues now have robust data-rich solutions, and leading scientists are reaping the benefits of an activity profiling approach. This thought leadership webinar brings together unique perspectives – from start-up to mid-size biotech and large global pharma – through discussion of challenges and achievements in implementing biomarker activity profiling strategies for pipeline progression. With audience Q&A, panelists will shed light on obvious, and less obvious, aspects of determining when a phenotypic approach can be beneficial, and how to integrate or supplement this innovation into a drug discovery and development strategy. Join Eurofins Discovery Phenotypic Center of Excellence for some serious fun.
- Learn how diverse drug development companies with unique models of discovery, innovative drug modalities, and non-traditional/natural product source material use phenotypic screening and profiling to understand their compounds' disease impact.
- Benefit from the experiences, challenges, and successes of others in bringing phenotypic approaches to target-based drug development programs.
Alison O’Mahony, Ph.D.
Vice President, Translational Biology
Lisa Schopf, Ph.D.
Stephanie Venn-Watson, DVM, MPH
Co-Founder, Chief Executive Officer
Kieron Edwards, MBA, Ph.D.
Chief Scientific Officer